PD Dr. med. Matthias Hepprich

• Hepprich M., Fischer J. et al. Canakinumab for the Treatment of Postprandial Hypoglycaemia: study protocol for a randomised, placebo-controlled, parallel-group, double-blind, multi-centric, superiority trial – The CanpHy Study, BMJ Open 04/2025
• Hepprich M, Roser P, et al. Awareness and knowledge of diabetic ketoacidosis in people with type 1 diabetes: a cross-sectional, multicenter survey. BMJ Open Diabetes Res Care. 2023 Nov;11(6):e003662. doi: 10.1136/bmjdrc-2023-003662. PMID: 37949471.
• Hepprich M., Mudry J. et al. (2022) Canakinumab in patients with COVID-19 and type 2 diabetes
  – a multicentre, randomised, double-blind, placebo-controlled trial. EClinicalMedicine. 2022 Sep 17;53:101649. doi: 10.1016/j.eclinm.2022.101649.
• Hepprich M, et al. (2022) Glucagon-Like Peptide-1 Receptor PET/CT in Patients with and Without Post Gastric Bypass Hypoglycemia: A Prospective, Matched Case-Control Study. J Gastrointest Dig Syst.12:686 DOI: 10.4172/2161-069X.1000686
• Zweck E., Hepprich M., Donath MY Predictors of Postprandial Hypoglycemia After Gastric Bypass Surgery: a Retrospective Case-Control Study. Obes Surg. 2021 Feb 23. doi: 10.1007/s11695-021-05277-1.
• Hepprich M. et al. Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Ther. 2021 Feb 22. doi: 10.1007/s13300-021-01016-y.
• Hepprich M. et al. Regular intake of energy drinks and multivitamin supplements is associated with elevated plasma vitamin B6 levels in post-bariatric patients. Sci Rep. 2021 Sep 8;11(1):17830. 
  doi: 10.1038/s41598-021-97205-7.  
• Hepprich M. et al. Patient involvement to inform the design of a clinical trial in postbariatric hypoglycemia (doi:10.21203/rs.3.rs-55915/v1, BMC Research Methodology)
• Hepprich M. et al. Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β. Cell Metab. 2020 Apr 7;31(4):699-709.e5.

Originalpublikationen – Co-Autorenschaften

• Pereira M, Hepprich M, et al. Arachidonic acid inhibition of the NLRP3 inflammasome is a mechanism to explain the anti-inflammatory effects of fasting. Cell Rep. 2024 Feb 27;43(2):113700. doi: 10.1016/j.celrep.2024.113700.
• Ferreira A, Hepprich M, et al. Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes Technol Ther. 2023 Jun 5. doi: 10.1089/dia.2023.0036. Epub ahead of print. PMID: 37093196.
• Schiavon M., Hepprich M. et al. Model-Based Assessment of C-Peptide Secretion and Kinetics in Post Gastric Bypass Individuals Experiencing Postprandial Hyperinsulinemic Hypoglycemia. Front Endocrinol (Lausanne). 2021 Mar 15;12:611253. doi: 10.3389/fendo.2021.611253.
• Koehler V., Hepprich M. et al. Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. Clin Endocrinol (Oxf). 2021 Nov 6. doi: 10.1111/cen.14617.
• Komminoth M, Hepprich M, et al; «TOASST» study group. Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST" (Taper Or Abrupt Steroid STop) multicenter trial. PLoS One. 2023 Apr 5;18(4):e0281585.
• Janiaud P., Hepprich M. et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis JAMA. 2021 Feb 26. doi: 10.1001/jama.2021.2747.
• Antwi K., Hepprich M. et al. Pitfalls in GLP-1 receptor imaging. Clin Nucl Med. 2020 Sep;45(9):e386-e392.
• Lehrskov L, Hepprich M. et al. The role of IL-1 in postprandial fatigue. Mol Metab. 2018 Apr 12. pii: S2212-8778(18)30106-6.
• Trinh B., Hepprich M. et al. Treatment of Primary Aldosteronism with mTORC1 inhibitors. J Clin Endocrinol Metab. 2019 May 14. pii: jc.2019-00563. doi: 10.1210/jc.2019-00563.

Reviews

• Hepprich M, Ebrahimi F, Christ E. Dyslipidemia and growth hormone deficiency - A comprehensive review. Best Pract Res Clin Endocrinol Metab. 2023 Sep 15:101821. doi: 10.1016/j.beem.2023.101821. Epub ahead of print. PMID: 37821339.
• Hepprich M. et al. Orale Antikoagulation und Thromboseprophylaxe bei adipösen und bariatrischen Patienten – eine Herausforderung. Review Swiss Medical Forum 2018;18(49):1038-1043

Case Reports

• Pfefferkorn F., Hepprich M. et al. Diabetische Ketoazidose unter Empagliflozin. Swiss Medical Forum 2019;19(29-30):473-475.
• Hepprich M. et al. Hypothyroidism manifesting as multiple cranial neuropathy. J Med Case Rep. 2019 Jun 13;13(1):180. doi: 10.1186/s13256-019-2124-6.
• Hepprich M. et al. Brunner’s gland hyperplasia in a patient after Roux-Y gastric bypass – an important pitfall in GLP-1 receptor imaging – a case report Case Rep Endocrinol. 2020; 2020: 4510910.

Buchkapitel

• Hepprich M., Meier C. Schilddrüsenerkrankungen. In: Der Risikopatient in der zahnärztlichen Praxis. Hrsg. J.T. Lambrecht, M. von Planta, 2017.
• M. Hepprich: Planung und Durchführung einer Vorlesung im klinischen Studienabschnitt: MOMBI in der Medizin in Tübinger Beiträge zur Hochschuldidaktik, Band 10/2, 2014, S. 41-46
• Hepprich M, Pfleger C. Infektionserkrankungen. In: AllEx – Alles fürs Examen: Das Kompendium für die 2. ÄP / Band A: Innere Medizin. Stuttgart: Thieme; 2012:481-568.